Your browser doesn't support javascript.
loading
Practice Advisory on the Appropriate Use of NSAIDs in Primary Care.
Ho, Kok Yuen; Cardosa, Mary S; Chaiamnuay, Sumapa; Hidayat, Rudy; Ho, Huynh Quang Tri; Kamil, Ozlan; Mokhtar, Sabarul A; Nakata, Ken; Navarra, Sandra V; Nguyen, Van Hung; Pinzon, Rizaldy; Tsuruoka, Shuichi; Yim, Heng Boon; Choy, Ernest.
Afiliação
  • Ho KY; The Pain Clinic, Mt Alvernia Hospital, Singapore.
  • Cardosa MS; Selayang Hospital, Batu Caves, Selangor, Malaysia.
  • Chaiamnuay S; Rheumatic Disease Unit, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.
  • Hidayat R; Rheumatology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia.
  • Ho HQT; Heart Institute, Ho Chi Minh City, Vietnam.
  • Kamil O; Gleneagles Hospital, Kuala Lumpur, Malaysia.
  • Mokhtar SA; Prince Court Medical Center, Kuala Lumpur, Malaysia.
  • Nakata K; Department of Orthopaedics and Traumatology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
  • Navarra SV; Department of Health and Sport Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Nguyen VH; Section of Rheumatology, Department of Medicine, University of Santo Tomas, Manila, Philippines.
  • Pinzon R; Department of Rheumatology, Bach Mai Hospital, Hanoi, Vietnam.
  • Tsuruoka S; Department of Neurology, Faculty of Medicine, Kristen Duta Wacana University, Bethesda Hospital, Yogyakarta, Indonesia.
  • Yim HB; Department of Nephrology, Nippon Medical School, Tokyo, Japan.
  • Choy E; Mount Elizabeth Novena Hospital, Singapore.
J Pain Res ; 13: 1925-1939, 2020.
Article em En | MEDLINE | ID: mdl-32821151
ABSTRACT
Cyclo-oxygenase (COX)-2 selective and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are important in managing acute and chronic pain secondary to inflammation. As a greater understanding of the risks of gastrointestinal (GI), cardiovascular (CV) and renal events with NSAIDs use has emerged, guidelines have evolved to reflect differences in risks among NSAIDs. Updated guidelines have yet to reflect new evidence from recent trials which showed similar CV event rates with celecoxib compared to naproxen and ibuprofen, and significantly better GI tolerability for celecoxib. This practice advisory paper aims to present consensus statements and associated guidance regarding appropriate NSAID use based on a review of current evidence by a multidisciplinary group of expert clinicians. This paper is especially intended to guide primary care practitioners within Asia in the appropriate use of NSAIDs in primary care. Following a literature review, group members used a modified Delphi consensus process to determine agreement with selected recommendations. Agreement with a statement by 75% of total voting members was defined a priori as consensus. For low GI risk patients, any nonselective NSAID plus proton pump inhibitor (PPI) or celecoxib alone is acceptable treatment when CV risk is low; for high CV risk patients, low-dose celecoxib or naproxen plus PPI is appropriate. For high GI risk patients, celecoxib plus PPI is acceptable for low CV risk patients; low-dose celecoxib plus PPI is appropriate for high CV risk patients, with the alternative to avoid NSAIDs and consider opioids instead. Appropriate NSAID prescription assumes that the patient has normal renal function at commencement, with ongoing monitoring recommended. In conclusion, appropriate NSAID use requires consideration of all risks.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2020 Tipo de documento: Article